China-based Hangzhou Baikai Biomedical Co., Ltd and Leads Biolabs Inc. have announced a partnership aimed at developing multiple novel antibody-drug conjugates (ADCs). The collaboration combines the expertise of both companies to advance the development of innovative cancer treatments. Financial details of the partnership have not been disclosed.
Baikai Bi’s ADC Expertise and Leads Bio’s Immunotherapy Focus
Baikai Bi, recognized as an ADC specialist, possesses multiple ADC platforms and has developed cytotoxins and linkers with new mechanisms of action (MoA). This expertise positions the company at the forefront of ADC technology. Concurrently, Leads Bio, a Sino-US biotech company, is dedicated to the research, development, and commercialization of second-generation tumor immunotherapy antibodies. Leads Bio boasts a robust product pipeline that includes more than 20 programs, reflecting its commitment to advancing immunotherapy solutions.
The Synergy of the Partnership
The partnership between Baikai Bi and Leads Bio is set to leverage the strengths of both companies, with Baikai Bi’s novel cytotoxins and linkers being combined with Leads Bio’s immunotherapy antibodies. This collaboration aims to create a new generation of ADCs that could significantly improve treatment outcomes for cancer patients. The joint efforts will focus on the development of cutting-edge therapies that harness the power of both ADCs and immunotherapy.-Fineline Info & Tech
